Title
Imaging biomarkers for antiangiogenic therapy in malignant gliomas

Permalink
https://escholarship.org/uc/item/2rg2r4qs

Journal
CNS oncology, 2(1)

Authors
Leu, K
Pope, WB
Cloughesy, TF
et al.

Publication Date
2013

DOI
10.2217/cns.12.29

Peer reviewed
Imaging biomarkers for antiangiogenic therapy in malignant gliomas

Kevin Leu¹, Whitney B Pope¹, Timothy F Cloughesy², Albert Lai², Phioanh L Nghiemphu², Wei Chen³, Linda M Liao⁴, and Benjamin M Ellingson*,¹,⁵,⁶

¹Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, 924 Westwood Boulevard, Suite 615, Los Angeles, CA 90024, USA
²Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
³Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
⁴Department of Neurosurgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
⁵Department of Biomedical Physics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
⁶Department of Biomedical Engineering, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA

SUMMARY

The discovery that malignant gliomas produce an excessive amount of VEGF, a key mediator of angiogenesis, has heightened interest in developing drugs that block angiogenic pathways. These antiangiogenic drugs tend to decrease vascular permeability, thereby diminishing tumor contrast enhancement independent of anti-tumor effects. This has made the determination of tumor response difficult, since contrast enhancement on post-contrast T₁-weighted images is standard for assessing therapy effectiveness. In light of these unique challenges in assessing antiangiogenic therapy, new biomarkers have been proposed, based on advanced magnetic resonance techniques and PET. This article outlines the challenges associated with the evaluation of antiangiogenic therapy in malignant gliomas and describes how new imaging biomarkers can be used to better predict response.

Primary brain tumors occur in approximately 18.7 out of 100,000 people per year and approximately 63,000 new cases are diagnosed in the USA per year [101]. Approximately 38% of all primary brain tumors are malignant and 32% are gliomas, which account for 80% of malignant primary brain tumors [101]. Glioblastoma (GBM) is a very aggressive form of primary brain tumor with a dismal prognosis, having a mean survival ranging from 12 to 14 months under the current standard of care of chemoradiotherapy – radiotherapy (RT) combined with concurrent chemotherapy using the alkylating agent, temozolomide (TMZ), along with adjuvant TMZ [1,2]. GBMs are highly vascularized, in part due to excessive levels of VEGF. This has in turn led to the targeting of VEGF and other angiogenic growth factors by a new class of antiangiogenic drugs, many of which are currently being studied in randomized clinical trials [3–5].

*Author for correspondence: Tel.: +1 310 481 7572; Fax: +1 310 794 8657; bellingson@mednet.ucla.edu.
The introduction of antiangiogenic therapies in the realm of GBM treatment has led to the reassessment [6] of conventionally defined tumor response criteria (i.e., the Macdonald criteria [7]). The Macdonald criteria use bidimensional measurements of enhancing tumor based on post-contrast T1-weighted MRI scans, taking advantage of the increased permeability observed in tumor vasculature. However, antiangiogenic therapies reduce the permeability of tumor capillaries, resulting in a reduction of contrast agent leakage into the extravascular, extracellular space [8]. At least half of GBM patients do not respond to antiangiogenic therapies, and the response time can vary widely [9], but almost all patients see a reduction in enhancement following anti-VEGF therapy. This decoupling of tumor response from changes in enhancing tumor volume has diminished the enthusiasm for standard imaging biomarkers for determining responses to antiangiogenic therapies in GBMs and other malignant gliomas. Research efforts in this area, with the purpose of improving medical decision-making and, ultimately, patient survival, are therefore needed.

**Antiangiogenic therapies in malignant gliomas**

Antiangiogenic therapies were originally hypothesized to eradicate tumors by destroying their underlying vasculature; however, studies have demonstrated that they are the most effective when combined with chemotherapy and RT [10]. In light of these results, a ‘vascular normalization’ theory has been proposed, where antiangiogenic therapies re-establish a more efficient vasculature by pruning away the most inefficient vessels [11,12]. Pericytes – cells that are crucial to the maintenance of the blood–brain barrier – are recruited when the VEGF receptor is blocked, thereby decreasing vascular permeability. The basement membrane seen in tumor vessels becomes thinner, increasing oxygenation of the tumor. These combined effects are thought to allow chemotherapeutics to perfuse the tumor more efficiently, resulting in a higher response rate.

Currently, only one antiangiogenic agent has been US FDA approved for use in the clinical setting: bevacizumab, a humanized monoclonal antibody for VEGF-A. In a 2009 Phase II trial of 167 recurrent GBM patients, bevacizumab was used alone or in combination with irinotecan, a topoisomerase inhibitor. Progression-free survival (PFS) rates at 6 months were 42.6 and 50%, respectively; this was a significant improvement over the historical baseline of 15% 6-month PFS with salvage chemotherapy [13]. Moreover, corticosteroid use was reduced over time in bevacizumab-treated patients [13]. As a consequence, bevacizumab was conditionally approved by the FDA in 2009 for use in patients with recurrent GBM [14,15].

Several additional antiangiogenic drugs have been explored in ongoing clinical trials. Cediranib, a small-molecule inhibitor of all VEGF subtypes, PDGF receptor and c-Kit [9], has a potential advantage over bevacizumab because of its oral bioavailability. In a Phase II trial of 31 patients, PFS at 6 months was 25.8% and a radiographic response was observed in 56.7% of patients [16]. Similar to bevacizumab, cediranib was associated with a reduction or discontinuation of corticosteroids. Another antiangiogenic agent currently under investigation is sorafenib, a small molecule that targets VEGF receptor, PDGF receptor and Raf kinase. A Phase II study in 2010 demonstrated no survival advantage when sorafenib was used in combination with RT and TMZ compared with RT and TMZ alone [17]. Pazopanib, a small-molecule inhibitor, was not shown to improve PFS in recurrent GBM patients [18]. Other antiangiogenic drugs currently under investigation include vatalanib [19] and vandetanib [20], which have undergone Phase I trials, both in combination with RT and TMZ in newly diagnosed GBM patients, and were generally well tolerated.

In summary, several antiangiogenic therapies appear to improve PFS compared with standard salvage chemotherapies. However, tumor progression is intimately tied to
radiographic response via contrast enhancement, which is directly altered by the mechanism of antiangiogenic therapies, which is potentially independent of their anti-tumor effects. This underscores the need for new imaging biomarkers aimed at quantifying the response to and predicting early failure of antiangiogenic therapies in malignant gliomas.

**Imaging biomarkers for malignant glioma response to antiangiogenic therapy**

**Response Assessment in Neuro-Oncology**

In 2010, Response Assessment in Neuro-Oncology (RANO) released the first white paper outlining updated response criteria for neuro-oncology [6] that aimed to address some of the limitations of the Macdonald criteria when evaluating antiangiogenic therapy. Specifically, the RANO criteria aimed to overcome the challenges associated with the significant reduction in contrast enhancement after bevacizumab treatment [13,21–23] by incorporating changes in T2-weighted or fluid-attenuated inversion recovery (FLAIR) images, as well as clinical variables, into the definition of tumor response; however, no specific thresholds for what constitutes ‘significant changes’ in T2/FLAIR images have been provided. In response to this lack of guidance in interpreting significant changes in T2/FLAIR hyperintense lesions, a few studies have attempted to verify and quantify the added benefit of incorporating specific thresholds for T2/FLAIR changes. For example, Radbruch et al. implemented two cut-offs, a 15 and 25% increase in T2 compared with baseline, or best response as a marker of tumor progression in 144 patients with recurrent malignant gliomas [24]. Results from this study suggested a threshold of a 15% change in bidirectional measurements of T2/FLAIR hyperintense lesions should be used for the evaluation of nonenhancing tumor growth. Additionally, Gállego Pérez-Larraya et al. performed a comprehensive comparative analysis of the Macdonald, Response Evaluation Criteria in Solid Tumors (RECIST), RANO and RECIST with FLAIR (RECIST + F) criteria [25]. In this study, investigators used a 20% increase in the largest diameter of the enhancing lesion for RECIST + F analysis and a 25% or more increase in the maximal cross-sectional area for RANO analysis. Results demonstrated that the inclusion of FLAIR reduced response rates by approximately 5% compared with their direct counterparts, and RANO and RECIST + F detected recurrence approximately 1 month before the Macdonald and RECIST criteria. These studies both indicate that incorporation of FLAIR into the RANO guidelines for tumor response appears to improve the accuracy of determining tumor progression; however, quantification of changes still remains an issue since precise quantification of infiltrating tumor from treatment effects or changes in edema can be challenging. Furthermore, the precise cut-off point for defining relevant T2 change remains controversial despite being critical for implementation. Choosing a cut-off point is a double-edged sword: a low cut-off for T2 changes may decrease the specificity by increasing the risk of misdiagnosis of progression (e.g., T2 changes due to radiation therapy, corticosteroids or post-operative changes) and a higher cut-off for T2 changes decreases the sensitivity by increasing the risk of not identifying nonenhancing tumor progression. A more sophisticated approach to determine the optimal cut-off (e.g., receiver operating characteristic curves) may be useful for resolving this debate.

Although most transient measures of treatment response for antiangiogenic therapies using standard magnetic resonance (MR) images are generally ascribed to changes in vascular permeability, there is also evidence for other radiographic changes that may reflect a favorable response to therapy. For example, subsets of bevacizumab patients (~5%) develop and maintain necrosis within the main lesion site as well as vascular control. These patients may develop persistent restricted diffusion lesions on diffusion MRI with relatively low cerebral blood volume PET tracer uptake, and appear to have a survival advantage compared
with matched patients without these lesions [26]. Additionally, an increase in $T_2$ hyperintensity or contrast enhancement could possibly reflect postradiation changes (i.e., pseudoprogression), which typically have a favorable prognosis.

Changes in radiographic features are likely to reflect the underlying molecular and micro-environmental changes within the tumor. For example, patients and animals that have nonenhancing tumor progression while being treated with antiangiogenic agents typically maintain low levels of VEGF, but may show evidence of increased hypoxic lesions as well as an increase in IGFB2 and MMP2 expression, indicative of tumor cell invasion [27]. This observation of increased infiltrating, nonenhancing tumor as evidenced by $T_2$ or FLAIR hyperintensity has been noted in many studies [27–29]; however, this topic remains controversial owing to other studies that support a lack of abnormal tumor invasion patterns [30,31]. Increased contrast enhancement, blood volume or vasculature during treatment with antiangiogenic agents may reflect activation of alternative angiogenic signaling pathways, such as bFGF, Tie-2 and DSF-1α, or recruitment of endothelial progenitor cells [32]. Because of these many confounds to traditional radiographic interpretation, integration of more sophisticated physiological imaging biomarkers or tumor segmentation techniques into the RANO criteria may be advantageous.

Quantitative volumetric analysis

Multiple studies have demonstrated the dramatic effects of bevacizumab on standard MRI, such as the reduction in vasogenic edema on $T_2$-weighted images and reduction in contrast enhancement (Figure 1) [29,33–35]. In a recent investigation into the volumetric changes in contrast enhancement and $T_2$ hyperintensity in 84 patients with recurrent GBM, it was demonstrated that, in patients treated with bevacizumab, patients with a post-treatment, contrast-enhancing volume of more than 15 ml were statistically more likely to progress sooner than patients with a lower volume of contrast enhancement [36]. This same study also showed that the relative nonenhancing tumor ratio (rNTR) – the ratio of FLAIR volume to contrast-enhancing volume – was a significant predictor of response. Specifically, the median PFS was 88 days for patients with a high rNTR ($\geq 7.5$) and 162.5 days for the patients with a low rNTR, whereas the same threshold demonstrated a median overall survival (OS) of 260 and 352 days for the high and low rNTR groups, respectively.

$T_2$ relaxometry

Antiangiogenic therapy results in a reduction of $T_2$ of $T_2$ hyperintense volume on standard $T_2$-weighted or FLAIR images; however, this reduction in observed hyperintense volume is directly related to changes in $T_2$ relaxation rates. In a recent study, a voxelwise subtraction technique was used to create differential quantitative $T_2$ maps (Figure 2) [37]. This study demonstrated that patients with a larger decrease in $T_2$ following first treatment with bevacizumab were more likely to have a longer PFS and OS. Furthermore, median post-treatment $T_2$ linearly correlated with PFS and OS. In general, however, the inability to predict clinical end points using the change in $T_2$ may suggest that the change in water concentration from vasogenic edema does not reflect changes in the tumor itself, but rather the change in vascular permeability. Regardless, differential quantitative $T_2$ maps may be advantageous for evaluating changes in tissue water content and provide another perspective from which to approach the assessment of the efficacies of antiangiogenic therapies.

Perfusion-weighted MRI biomarkers

Given that malignant gliomas thrive by co-opting the pre-existing vasculature and by inducing new vessel formation, perfusion-weighted MR techniques are an intriguing tool for uncovering the change in vascularity that may result from antiangiogenic therapy; however, very few studies have actually employed perfusion-weighted MRI to study antiangiogenic
therapies. Dynamic susceptibility contrast-enhanced MRI utilizes the first pass of MRI (paramagnetic) contrast to estimate the relative cerebral blood volume (rCBV) and relative cerebral blood flow (rCBF). Pechman et al. have used rCBV as a measure of therapeutic responses to bevacizumab and combination therapy in a U87 brain tumor murine model [38]. In one study, they used different concentrations of bevacizumab, 0.0, 2.5, 5.0 and 10.0 mg/kg, to determine the potential effects on tumor volume and rCBV [38]. Results suggested that rCBV decreased with treatment as early as 2 days after therapy, but changes in enhancing tumor volumes from post-contrast T1-weighted images were delayed in comparison. In a subsequent study they compared bevacizumab (5 mg/kg) to combination therapy with irinotecan (20.83 mg/kg) and observed a rCBV decrease between 4 and 6 days after therapy, followed by a rebound effect [38]. The authors suggest this may be indicative of the ‘vascular normalization window’, which was further supported by histological visualization of the vessel densities, which were found to be similar between the bevacizumab and control groups. Overall, results from these preclinical studies show the potential utility of rCBV as a biomarker for changes in vascularity known to accompany antiangiogenic therapy.

Although only a single human study has directly examined the prognostic capabilities of rCBV and rCBF to predict response to anti-angiogenic therapies [39], unpublished data from our institution suggest that a decrease in rCBV in the weeks following bevacizumab treatment reflects a favorable patient response (rCBV maps and cerebral blood volume parametric response maps after bevacizumab treatment are illustrated in Figure 3) [Lax K et al., UNPUBLISHED DATA]. Sorensen et al. noted that patients with an increase in rCBF have a favorable prognosis due to the normalization of abnormal blood vasculature leading to more efficient perfusion [39], which has been evidenced in other studies [40]. This may seem to contradict our observations of rCBV, but both rCBF and rCBV are related to each other via the mean transit time (MTT) of blood through the image voxel (rCBV = rCBF × MTT).

Thus, the observation that a decrease in rCBV and an increase in rCBF are implicated in better prognosis intrinsically implies a reduction in MTT, probably as a result of decreased tortuosity of tumor neovasculature after antiangiogenic therapy. Additionally, data from our institution show that recurrence after bevacizumab treatment results in increased rCBV relative to the first post-treatment assessment (but lower than recurrence when antiangiogenic agents were not used). This increase in rCBV at recurrence probably reflects the aforementioned alternative angiogenic escape pathways and may provide an early indication of treatment failure.

As an alternative to traditional dynamic susceptibility contrast-enhanced MRI analysis, Essock-Burns et al. examined the ability of two MRI-derived parameters to predict the response to antiangiogenic therapies and identify early predictors of progression: relative peak height, a measure of vascularization; and percentage of signal intensity recovery, a gauge of capillary permeability [41]. The percentage recovery was defined as the relative return of the bolus enhancement curve to baseline. Essock-Burns et al. found that a unit increase in peak height above the 90th percentile during the first month was associated with a fivefold greater risk of progression. On the other hand, a greater than 25th percentile recovery at 2 months from baseline was correlated with a longer PFS. The authors reported that 4 months prior to progression, the heterogeneity of percentage recovery values within the tumor region increased, as assessed by the standard deviation of percentage recovery. The prediction of tumor progression may be particularly useful for clinicians, although the method of assessing heterogeneity of percentage recovery values should be tested in larger trials.

Dynamic contrast-enhanced MRI, another perfusion MRI technique, uses a simple pharmacokinetic model to estimate gadolinium contrast agent transfer rates and compartment
volumes from dynamic T₁-weighted images. Kreisl et al. used dynamic contrast-enhanced MRI as a secondary biomarker for evaluating the activity of single-agent bevacizumab in patients with recurrent anaplastic gliomas [42]. As soon as 4 days after administration of bevacizumab, there was a 30.8% decrease in the transfer rate from the intravascular space to the extravascular space (Ktrans), which is a surrogate for vascular permeability [43], and a 21.4% decrease in fractional plasma volume. By 4 weeks, Ktrans had decreased by an average of 51.9% and the mean fractional plasma volume decreased by 45.9% compared with pretreatment levels. Despite the significant reduction in quantitative vascular parameters, neither Ktrans nor fractional plasma volume were predictive of patient outcome or survival. Sorensen et al. showed a similar decrease in Ktrans and fractional plasma volume following administration of cediranib, along with a weak association between change in Ktrans and patient survival [44]. They also found that by combining Ktrans with biological assays, they could estimate the vascular normalization window and better predict patient survival than with quantitative imaging parameters alone. By combining Ktrans, biological assays and collagen IV levels, Sorensen and colleagues demonstrated a multiparametric tool for predicting early response to antiangiogenic therapy and estimating patient survival.

Farrar et al., using an orthotopic mouse glioma model, strove to demonstrate the sensitivity of the MRI perfusion biomarkers that putatively predict outcomes [45]. They found that the most sensitive measures were T₂, rCBV, relative microvascular blood volume (rMBV) and Ktrans. The T₂ changes that are assumed to reflect the differences in tumor water content were indeed correlated with ex vivo measurements of tumor water. Intravitreal optical microscopy measures were used to confirm the sensitivity of rCBV and Ktrans values. In cediranib-treated mice, the authors observed that the rMBV decreased more than rCBV did. On the other hand, rCBV increased and rMBV decreased for the untreated mice. This suggests that cediranib may preferentially prune the smaller, less well-developed tumor blood vessels. This proof-of-principle study confirms that perfusion-based MR biomarkers are indeed sensitive to changes in tumor vascularity and may be useful for measuring response to new antiangiogenic agents.

Although an extensive review is outside the scope of this article, the development of new customized contrast agents, nanospheres, functional agents and novel blood pool agents offers the possibility of further characterizing the vascular pores in normal and tumor vasculature [46]. For example, Henderson et al. developed a technique for using two different gadolinium contrast agents with very different molecular weights (gadolinium-diethylene triamine pentaacetic acid, 0.6 kDa, and 24-gadoliniummacrocyclic dendrimer, 17 kDa) to estimate blood flow, volume and vascular permeability in breast lesions [47]. Alternatively, the use of iron oxide particles with different sizes, charges and surface structures could provide insight into changes in vascular permeability beyond that of traditional contrast agents.

**Diffusion-weighted MRI biomarkers**

Diffusion-sensitive MRI techniques are another imaging method that has shown promise in predicting response to standard cytotoxic as well as modern antiangiogenic therapies. Diffusion-weighted imaging is sensitive to microscopic, subvoxel water motion for which an apparent diffusion coefficient (ADC) can be estimated, reflecting the magnitude of water motion. ADC has been shown to be inversely correlated with tumor cell density [48–55], largely as a result of restriction of extracellular water motion caused by tightly packed tumor cells. Given that brain neoplasms have a higher cell density than normal tissues, they have lower ADC values. On the other hand, edema and necrosis, which are associated with lower cell densities, have relatively higher ADC values.
Consistent with this hypothesis, Pope et al. utilized the distribution of ADC values within pretreatment contrast-enhancing regions to predict the response to bevacizumab [56]. Specifically, this study fit a double Gaussian mixture model to the ADC histogram extracted from pretreatment contrast-enhancing regions and noted that the mean of the lower ADC histogram (ADC<sub>L</sub>) was a significant predictor of PFS. Specifically, this study noted that patients with a lower mean ADC<sub>L</sub> were more likely to develop resistance to bevacizumab treatment earlier than patients with a higher mean ADC<sub>L</sub>. In a follow-up multicenter study, Pope et al. applied the double Gaussian mixture model in 97 recurrent GBM patients [57]. Consistent with the smaller study, lower mean ADC<sub>L</sub> values were correlated with shortened survival. Meanwhile, a combined mean ADC<sub>L</sub> score <1.209 µm²/ ms and a lower curve proportion >0.71 was associated with a 2.28-fold reduction in median time to progression and a 1.42-fold decrease in median OS. This study is the first to confirm the potential clinical usefulness of ADC histogram analysis; although standardizing the imaging methodology and submitting it to further prospective evaluations can help optimize this biomarker. Interestingly, Pope et al. also applied this same technique to newly diagnosed GBM patients treated with bevacizumab and found somewhat opposite trends [58]. Specifically, GBM patients with a higher ADC<sub>L</sub> actually had a lower PFS compared with patients with a lower ADC<sub>L</sub>. These results were attributed to patients with a lower ADC<sub>L</sub> being more likely to have the <i>MGMT</i> promoter methylated, which is favorable for chemoradiotherapy; however, the basis for this discrepancy still warrants investigation.

Voxelwise changes in ADC have also been utilized as a potential biomarker for response to antiangiogenic therapy using a technique termed functional diffusion mapping [59,60]. Specifically, functional diffusion maps (fDMs) are created by quantifying the voxelwise changes in ADC after co-registration of ADC maps from different time points. Although fDMs have been applied to cytotoxic therapy, Ellingson et al. were the first to use fDMs to assess antiangiogenic therapy [61,62]. In one study, the investigators used ‘graded’ fDMs, as shown in Figure 4, in which multiple ΔADC thresholds were used to generate fDMs to demonstrate that a decrease in ADC between 0.25 and 0.40 µm²/ ms recorded in a larger volume than that seen in the group median within the FLAIR regions of interest had a poor prognosis. Graded fDMs also produced a higher sensitivity (58%) and specificity (67%) than the traditional fDMs (56 and 63%, respectively) with respect to the 12-month OS in recurrent GBM patients treated with bevacizumab.

In another fDM study, Ellingson et al. explored the possible utility of a nonlinear registration scheme, registering the post-treatment ADC map to the pretreatment one, and vice versa [63]. This study found that the ‘pre-to-post’ nonlinear registration scheme applied to FLAIR regions provided the best stratification between short- and long-term PFS and OS, and had the highest hazard ratio. Furthermore, the ‘pre-to-post’ scheme had a higher sensitivity (64%) and specificity (73%) for 6-month PFS and 12-month OS in recurrent GBM patients treated with bevacizumab than linear fDMs (59 and 67%, respectively). Interestingly, the volume fraction of tissue within the FLAIR regions of interest having an increased ADC was significantly different between linear and non-linear registration techniques, further improving the ability of the fDMs to predict response to bevacizumab in recurrent GBMs.

Since ADC is believed to be a surrogate for tumor cell density, serial ADC maps can be used to generate estimates of tumor cell proliferation and invasion rate using cell invasion, motility and proliferation level estimate (CIMPLE) maps [62,64]. Figure 5 shows proliferation maps for a patient treated with bevacizumab. Investigators retrospectively studied 26 recurrent GBM patients treated with bevacizumab and noted a linear correlation between the mean proliferation rate, PFS and OS. A mean proliferation rate of 3.73 per year was used to stratify patients, resulting in a median PFS of 100.5 days for highly proliferative
tumors and 401 days for tumors with a lower proliferation rate. Similarly, patients with a high proliferation rate had a median OS of 286 days, while patients with a low proliferation rate had a median OS of approximately 711.5 days. Most notably, CIMP LE maps were also able to spatially predict regions of future tumor recurrence in nearly a third of patients, which demonstrates the potential of CIMP LE maps as a predictive biomarker in antiangiogenic therapy.

**MR spectroscopic biomarkers**

MR spectroscopy can be used to quantify the levels of important biochemical metabolites within tumors, including choline (Cho), a molecule associated with cell turnover and proliferation; N-acetyl aspartate (NAA), a molecule associated with healthy neurons; and lipids and lactate, molecules associated with degradation of myelin and cell membrane structures. Kim *et al.* investigated the MR spectral profiles of 31 patients with recurrent GBM during and after treatment with cediranib, noting a ratio of NAA:Cho in contrast-enhancing tumor regions of 2.4 and 5.0, respectively, in normal-appearing brain tissue [65]. During the first 28 days of cediranib treatment, the time period believed to be associated with the vascular normalization window, investigators observed consistency of the NAA:Cho ratio, suggesting tumor cells are not destroyed during this time frame, but rather cediranib acts solely by decreasing vascular permeability. A significant increase in NAA:Cho occurred after 28 days and patients with a positive change in NAA:Cho had a better OS than those with negative values at days 28 and 56, supporting the notion of using MR spectroscopy to monitor antiangiogenic treatment response.

**PET imaging biomarkers**

PET scans have also been explored in the context of identifying biomarkers for response to antiangiogenic therapies. For many malignant tumors, $^{18}$F-fluorodeoxyglucose ($^{18}$F-FDG) is used as the radiotracer of choice for PET scans as it can be used to quantify glucose uptake and metabolism. Colavolpe *et al.* recently used pretreatment $^{18}$F-FDG to predict survival in 25 recurrent high-grade glioma patients treated with bevacizumab and irinotecan [66]. They investigated two different PET parameters: the tumor maximal standardized uptake value within a region of interest (SUV$_{max}$) and the ratio between tumor and symmetric contralateral SUV$_{max}$ (T:CL). Univariate analysis showed that SUV$_{max}$ >7 and T:CL ratio >1.348 were statistically significant for PFS and OS. Multivariate analysis confirmed SUV$_{max}$ and T:CL ratio as predictors of PFS and OS, regardless of histological grade. $^{18}$F-FDG was also recently used as a secondary imaging biomarker in a Phase II trial of bevacizumab in 31 recurrent anaplastic gliomas [42]. Contradictory to the findings by Colavolpe *et al.* [66], this study did not find pretreatment $^{18}$F-FDG uptake to be a significant predictor of PFS or OS when performing multi-variate analysis; however, the $^{18}$F-FDG uptake 4 weeks after starting therapy was found to be a significant predictor of PFS, but not OS. Interestingly, average $^{18}$F-FDG uptake was only approximately 4% lower 4 weeks following bevacizumab and a decrease in uptake was only observed in approximately 50% of patients. The change in uptake was also not found to be a significant predictor of OS. Unpublished data from our institution suggest that $^{18}$F-FDG uptake is elevated at the time of radiographic recurrence in almost all patients on bevacizumab, regardless of their initial response [Liu *et al.*, UNPUBLISHED DATA]. Figure 6 shows an example of $^{18}$F-FDG PET uptake in a patient who progressed on bevacizumab, showing elevated uptake in regions of recurrent tumor.

Another radiotracer that has been explored in the context of antiangiogenic therapy in malignant gliomas is the thymidine analog, 3′-deoxy-3′-$^{18}$F-fluorothymidine ($^{18}$F-FLT), which allows for more direct quantification of proliferation rates through expression of the enzyme thymidine kinase-1 during DNA synthesis [67]. In a pilot study, $^{18}$F-FLT was
explored as an imaging biomarker for separating bevacizumab responders from nonresponders [68]. In a follow-up study, Schwarzenberg et al. compared 18F-FLT uptake with results from MRI scans in 30 patients with recurrent high-grade gliomas treated with bevacizumab and irinotecan [69]. A decrease in 18F-FLT uptake of ≥25% was deemed to be a successful treatment response. The authors found that the uptake changes at 2 and 6 weeks post-treatment were predictive of both PFS and OS. The patients identified as responders, according to 18F-FLT uptake, lived 3.3-times longer than their nonresponder counterparts, compared with a 1.4-fold increase in survival for MRI responders compared with nonresponders. Interestingly, there were discrepancies between the MRI and PET results. For example, of the seven patients that were classified as nonresponders to MRI but were responders to PET, survival was 12.3 months, in line with the responders’ survival times. On the other hand, the one responder to MRI, but not PET, survived only 2.8 months. This demonstrates that 18F-FLT PET may be capable of identifying treatment responders earlier than MRI. Figure 7 shows an example of 18F-FLT uptake in a patient treated with bevacizumab, illustrating an initial decrease in uptake following therapy.

In a recent study, Harris et al. demonstrated the power of examining voxelwise changes in PET uptake, termed PET parametric response maps, by examining changes in both 18F-FLT and 3,4-dihydroxy-6-18F-fluoro-l-phenylalanine (18F-FDOPA), an amino acid tracer [70]. Receiver operating characteristic analysis revealed that patients with a large volume of increased 18F-FDOPA uptake after treatment with bevacizumab had a shorter PFS and OS. Additionally, a high volume of decreased uptake in both tracers had a high sensitivity (91% for 18F-FDOPA and 90% for 18F-FLT) for predicting 3-month PFS and 6-month OS. These studies clearly demonstrate the potential for more sophisticated analyses of PET data to predict response to antiangiogenic therapy.

**Conclusion & future perspective**

Within the last few years, treatment strategies for malignant gliomas have combined RT and chemotherapy with new antiangiogenic drugs. This paradigm shift highlights the need for sensitive imaging biomarkers to identify changes in the tumor independent of contrast enhancement. To overcome this challenge, researchers have begun developing and testing a myriad of imaging biomarkers for patient treatment response by examining multiple biological perspectives and pathways. The intent of these studies is largely to provide new tools for evaluating new antiangiogenic drugs, provide clinicians with information to make earlier treatment decisions and, ultimately, to improve malignant glioma patient survival. Since a subset of patients in most clinical trials evaluating the use of antiangiogenic drugs have a complete radiographic response to therapy and may have significantly longer survival, this population may offer the chance to optimize imaging biomarkers to detect a ‘true’ complete response earlier than traditional techniques.

Given that most of these studies into new biomarkers were performed retrospectively in relatively small trials, prospective studies in larger clinical trials are necessary to validate and optimize the use of these imaging biomarkers so that they may enter clinical practice. Yet, given the modest success that antiangiogenic therapies have had thus far, glioma treatment methods will probably continue to evolve. As the landscape of tumor treatment changes over time, certain imaging modalities and measurements may need to be modified to reflect true tumor response. New imaging biomarkers must continue to take up the mantle to better reflect patient prognoses as our understanding of malignant glioma biology and treatment responses advances.
Acknowledgments

Financial & competing interests disclosure

The authors acknowledge the following funding: University of California, Los Angeles (UCLA) Institute for Molecular Medicine Seed Grant, UCLA Radiology Exploratory Research Grant, UCLA Cancer Research Coordinating Committee Grant and American College of Radiology Imaging Network (ACRIN) Young Investigator Initiative Grant to BM Ellingson; Art of the Brain, Ziering Family Foundation in memory of Sigi Ziering, Singleton Family Foundation and Clarence Klein Fund for Neuro-Oncology to TF Cloughesy; and NIH National Institute of General Medical Sciences (NIGMS) training grant GM08042 and UCLA Medical Scientist Training Program to K Leu. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

References

Papers of special note have been highlighted as:

■ of interest
■■ of considerable interest


45. Used a combined dynamic contrast-enhanced MRI imaging biomarker and biological assay to predict response to antiangiogenic therapy.


62. Used a novel diffusion MRI biomarker to evaluate the glioblastoma response to bevacizumab.


CNS Oncol. Author manuscript; available in PMC 2014 February 23.


■ Website

Practice Points

- In most glioblastoma patients, antiangiogenic therapy reduces the amount of T2 and fluid-attenuated inversion recovery (FLAIR) hyperintensity and contrast enhancement on post-contrast T1-weighted images; however, this may be independent of any actual ‘anti-tumor’ effects.

- The Response Assessment in Neuro-Oncology Group and individual institutions have implemented changes in T2/FLAIR lesions as part of the definition of tumor progression in the context of antiangiogenic therapy, and suggested a 15–25% change in bidirectional measurements may be sufficient for defining disease progression.

- Residual T2 or FLAIR hyperintensity and contrast enhancement after the initial round of antiangiogenic treatment is a simple yet powerful predictor of tumor burden and a surrogate of survival.

- A decrease in cerebral blood volume, increase in cerebral blood flow, decrease in vascular mean transit time and decrease in vascular permeability (Ktrans) after initial therapy, as measured with perfusion MRI, suggest a favorable response to antiangiogenic therapy.

- Recurrent malignant gliomas with a low apparent diffusion coefficient within areas of contrast enhancement prior to antiangiogenic therapy progress nearly twice as fast as tumors with a higher apparent diffusion coefficient.

- PET assessment of tumors after initiation of antiangiogenic therapy is useful for predicting long-term response and survival.
Figure 1. Anatomical MRI response to antiangiogenic therapy
FLAIR: Fluid-attenuated inversion recovery.
Figure 2. Differential quantitative $T_2$ response to antiangiogenic therapy
$T_2$ relaxation rate color maps are calculated using multiecho fast spin-echo acquisition. Differential quantitative $T_2$ images illustrate the voxelwise difference in $T_2$ measurements. Note that $T_2$ has increased along the right boundary of the contrast-enhancing lesion, as shown in red.
Figure 3. Effects of antiangiogenic therapy on relative cerebral blood volume
(A) Post-contrast T1-weighted magnetic resonance images. (B) Leakage-corrected and standardized rCBV color maps. (C) rCBV PRMs showing voxelwise changes in rCBV after antiangiogenic therapy. Red/yellow indicates an increase in rCBV, while blue/cyan indicates a decrease.

CNS Oncol. Author manuscript; available in PMC 2014 February 23.
Figure 4. Functional diffusion map response to antiangiogenic therapy
ADC maps were calculated from diffusion magnetic resonance images. Graded fDMs show a decrease in ADC along the edge of the enhancing tumor. Blue/cyan indicates a decrease in ADC, while yellow/red indicates an increase.
Figure 5. Cell invasion, motility and proliferation level estimate map response to antiangiogenic therapy
CIMPLE map estimates of proliferation rate show elevated proliferation within the region of contrast enhancement.
CIMPLE: Cell invasion, motility and proliferation level estimate; FLAIR: Fluid-attenuated inversion recovery.
Figure 6. $^{18}$F-fluorodeoxyglucose PET uptake at recurrence after antiangiogenic therapy

$^{18}$F-FDG PET–MR fusion images show co-localization of elevated $^{18}$F-FDG in the medial contrast-enhancing nodule. $^{18}$F-FDG PET uptake images show elevated $^{18}$F-FDG uptake within the tumor areas.

$^{18}$F-FDG: $^{18}$F-fluorodeoxyglucose; MR: Magnetic resonance; SUV: Standardized uptake value.
Figure 7. 3'-deoxy-3'-18F-fluorothymidine PET response to antiangiogenic therapy

18F-FLT PET images show reduced uptake after antiangiogenic therapy and a sustained decrease in uptake relative to baseline (pretreatment) levels.

18F-FLT: 3'-deoxy-3'-18F-fluorothymidine; FLAIR: Fluid-attenuated inversion recovery; SUV: Standardized uptake value.